The study will be a single centre, open-label trial. The patients will have a diagnosis of
refractory ascites and will meet specified inclusion/exclusion criteria Informed consent will
be obtained from all patients. All patients will have an alfapump surgically inserted and in
addition will receive 8g of salt-poor Human Albumin Solution (20%) per 1 litre of Ascites
drained. This Intravenous administration will be intermittent (every month) and will take
place as a day patient. Patients will also receive standard of care, which may include, but
is not limited to, administration of diuretics, paracentesis and consideration for orthotopic
liver transplantation.